Cargando…

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?

Detalles Bibliográficos
Autores principales:	Lee, Kuan-Yu, Hsu, Chen-Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087986/ https://www.ncbi.nlm.nih.gov/pubmed/37057113 http://dx.doi.org/10.21037/tlcr-22-897

Ejemplares similares

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: He, Jiaxi, et al.
Publicado: (2015)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences
por: Xu, Fei, et al.
Publicado: (2022)

Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
por: Cao, Shuhui, et al.
Publicado: (2018)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
por: Matsuo, Koji, et al.
Publicado: (2017)

Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer
por: Tu, Zegui, et al.
Publicado: (2021)

Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
por: Jang, Hyo Joon, et al.
Publicado: (2017)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
por: Xu, Yangyang, et al.
Publicado: (2022)

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer
por: Li, Da-Peng, et al.
Publicado: (2015)

A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
por: Song, Xue, et al.
Publicado: (2023)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma
por: Xie, Yangyang, et al.
Publicado: (2023)

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
por: Park, Seong Yong, et al.
Publicado: (2013)

Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis
por: Wang, Xiaofan, et al.
Publicado: (2021)

Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy
por: Singh, Sareena, et al.
Publicado: (2015)

Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
por: Choi, Juwhan, et al.
Publicado: (2022)

Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?
por: Passiglia, Francesco, et al.
Publicado: (2023)

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
por: Tang, Wen-Fang, et al.
Publicado: (2023)

Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB–IIA cervical cancer patients
por: Lee, Kwang-Beom, et al.
Publicado: (2018)

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022)

Some light in the grey zone?
por: Bickenbach, J., et al.
Publicado: (2017)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer
por: Chen, Jenny Ling-Yu, et al.
Publicado: (2021)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada, Naoko, et al.
Publicado: (2020)

Prognostic value of ESR2 expression on adjuvant chemotherapy in completely resected NSCLC
por: Yu, Hongliang, et al.
Publicado: (2020)

Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
por: Ou, Wei, et al.
Publicado: (2023)

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
por: Liang, Sheng‐Kai, et al.
Publicado: (2023)

Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer
por: Yao, Yuanshan, et al.
Publicado: (2019)

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
por: Herbst, Roy S., et al.
Publicado: (2023)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c1fr7dbrd0jk59tlk9objhjkvt